Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28657375 | 0.87 | GABBR2 (0.50) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL28014435 | 0.86 | SMN1; SMN2 (0.45) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL1892710 | 0.84 | SMN1; SMN2 (0.40) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL21046175 | 0.82 | SMN1; SMN2 (0.50) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL21046173 | 0.80 | SMN1; SMN2 (0.54) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL15474967 | 0.79 | PRKCA (0.53) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL8904725 | 0.79 | HDAC3 (0.47) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL1532583 | 0.78 | TLR2 (0.44) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL28604790 | 0.78 | LMNA (0.48) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 | |
| SCHEMBL1172092 | 0.78 | TLR2 (0.44) | CYP2D6SMN1; SMN2CYP1A2PKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838522-B1 | PHENYLBUTYRATE FOR THE TREATMENT OF MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2024-02-21 | — | — | EP | claimed |
| US-11786494-B2 | Methods of modulation of branched chain acids and uses thereof | BAYLOR COLLEGE OF MEDICINE (US) | 2023-10-17 | — | — | US | claimed |
| US-20200147016-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | ACER THERAPEUTICS INC. | 2020-05-14 | — | — | US | claimed |
| US-20190151268-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | ACER THERAPEUTICS INC. | 2019-05-23 | — | — | US | claimed |
| EP-2456304-B1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | BAYLOR COLLEGE MEDICINE (US) | 2015-08-19 | — | — | EP | claimed |
| US-20240238230-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | BAYLOR COLLEGE OF MEDICINE | 2024-07-18 | — | — | US | disclosed |
| EP-2838522-B1 | PHENYLBUTYRATE FOR THE TREATMENT OF MEDIUM-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2024-02-21 | — | — | EP | disclosed |
| US-11786494-B2 | Methods of modulation of branched chain acids and uses thereof | BAYLOR COLLEGE OF MEDICINE (US) | 2023-10-17 | — | — | US | disclosed |
| EP-3222275-B1 | METHODS OF THERAPEUTIC MONITORING OF PHENYLACETIC ACID PRODRUGS | IMMEDICA PHARMA AB (SE) | 2020-06-24 | — | — | EP | disclosed |
| US-20200147016-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | ACER THERAPEUTICS INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190151268-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | ACER THERAPEUTICS INC. | 2019-05-23 | — | — | US | disclosed |
| US-10092532-B2 | Methods of modulation of branched chain acids and uses thereof | BAYLOR COLLEGE OF MEDICINE (US) | 2018-10-09 | — | — | US | disclosed |
| US-20120022157-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | UCYCLYD PHARMA, INC (US) | 2012-01-26 | — | — | US | disclosed |
| EP-2338050-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | Ucyclyd Pharma, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-2330892-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | Ucyclyd Pharma, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011011781-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010025303-A9 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010025303-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100008859-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | HORIZON THERAPEUTICS U.S. HOLDING LLC | 2010-01-14 | — | — | US | disclosed |
| WO-2009134460-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | HYPERION THERAPEUTICS (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151268-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | OAT, ABAT, BCKDK | CYP2D6 2419/4885SMN1; SMN2 280/4885CYP1A2 2234/4885 |
| US-20240238230-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | OAT, ABAT, BCKDK | CYP2D6 2419/4885SMN1; SMN2 280/4885CYP1A2 2234/4885 |
| US-10092532-B2 | Methods of modulation of branched chain acids and uses thereof | OAT, ABAT, BCKDK | CYP2D6 2419/4885SMN1; SMN2 280/4885CYP1A2 2234/4885 |
| US-20120022157-A1 | DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS | PLPBP, GLS, NPPA | CYP2D6 199/4885SMN1; SMN2 2688/4885CYP1A2 366/4885 |
| US-20100008859-A1 | METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS | OAT, SLC1A5, GLS | CYP2D6 392/4885SMN1; SMN2 2015/4885CYP1A2 514/4885 |
| US-20200147016-A1 | METHODS OF MODULATION OF BRANCHED CHAIN ACIDS AND USES THEREOF | OAT, ABAT, BCKDK | CYP2D6 2419/4885SMN1; SMN2 280/4885CYP1A2 2234/4885 |
| US-11786494-B2 | Methods of modulation of branched chain acids and uses thereof | OAT, ABAT, BCKDK | CYP2D6 2419/4885SMN1; SMN2 280/4885CYP1A2 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.